Aclaris Therapeutics, Inc. (ACRS) Total liabilities 2017–2025
Aclaris Therapeutics, Inc. (ACRS) total liabilities at each fiscal year-end, per SEC filings.
$57.4MFY2025 · since FY2017: $18.2M → $57.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $57.4M | -11.4% |
| FY2024 | $64.8M | +61.0% |
| FY2023 | $40.2M | -29.4% |
| FY2022 | $57.0M | +5.8% |
| FY2021 | $53.9M | +62.6% |
| FY2020 | $33.1M | +16.7% |
| FY2019 | $28.4M | -53.0% |
| FY2018 | $60.4M | +231.2% |
| FY2017 | $18.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice